Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martínez-Yélamos, S
Right arrow Articles by Arbizu, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martínez-Yélamos, S
Right arrow Articles by Arbizu, T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Multiple Sclerosis, Vol. 12, No. 6, 826-829 (2006)
DOI: 10.1177/1352458506070820
© 2006 SAGE Publications

Regression to the mean in multiple sclerosis

S Martínez-Yélamos

Multiple Sclerosis Unit, Service of Neurology, Hospital Universitari de Bellvitge, IDIBELL, l’Hospitalet de Llobregat, Barcelona 08907, Spain

A Martínez-Yélamos

Service of Neurology, Hospital de Viladecans, Viladecans, Barcelona 08840, Spain

G Martín Ozaeta

Multiple Sclerosis Unit, Service of Neurology, Hospital Universitari de Bellvitge, IDIBELL, l’Hospitalet de Llobregat, Barcelona 08907, Spain

V Casado

Multiple Sclerosis Unit, Service of Neurology, Hospital Universitari de Bellvitge, IDIBELL, l’Hospitalet de Llobregat, Barcelona 08907, Spain

O Carmona

Service of Neurology, Hospital de Figueres, Girona 17600, Spain

Tx Arbizu

Multiple Sclerosis Unit, Service of Neurology, Hospital Universitari de Bellvitge, IDIBELL, l’Hospitalet de Llobregat, Barcelona 08907, Spain, unitatem{at}scs.csub.es

In order to ensure sufficient disease activity, patients with relapsing remitting (RR) multiple sclerosis (MS) are often included in randomized placebo-controlled trials, only if they have a high baseline activity. These patients, whose evolution is unusual in the pre-study period, will tend to show a more usual behavior when followed up over a period of time. This phenomenon is known as regression to the mean. Regression to the mean should be taken into account in correctly interpreting long-term studies of cohorts treated without a placebo control group, which use the baseline period as control. The aim of this study was to evaluate the relevance of this phenomenon in a non-treated cohort of RRMS patients, selected with similar criteria to those used in randomized placebo-controlled clinical trials. Forty-four patients with definite RRMS, with two or more relapses in the previous two years, and a baseline EDSS ≤ 5.5 were prospectively followed. The mean number of relapses spontaneously decreased from 1.72 (SD: 1.4) in the year prior to enrolment, to 1.0 (SD: 1.3) during the first year of follow-up (PB < 0.05). Regression to the mean may explain as much as 40% of the reduction in the relapse rate from the baseline period to the period on-study.

Key Words: disability • glatiramer acetate • interferon beta • multiple sclerosis • randomized clinical trials • regression to the mean


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
NeurologyHome page
Y. Zhao, A. Traboulsee, A. J. Petkau, and D. Li
Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis
Neurology, March 25, 2008; 70(13_Part_2): 1092 - 1097.
[Abstract] [Full Text] [PDF]